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INTRODUCTION 
 Treatment option for Chronic Kidney Disease-Stage5 (CKD-stage5) patients 
fall into three categories viz., Haemodialysis, Peritoneal dialysis and Renal 
Transplantation.  Many studies proved that the kidney transplantation is distinctly 
superior and it is associated with reduced mortality and morbidity compared to 
haemodialysis or peritoneal dialysis.  
 The renal donors are of three types viz. live related, live unrelated and 
cadaver. Due to shortage organs and long waiting period in cadaver transplant 
prevention of second or re transplant is more important. To improve the graft survival 
identifying etiology of graft dysfunction or loss is more important. Once we identified 
the etiology we have to evaluate for immunologic, nonimmunologic, modifiable, non 
modifiable risk factors to improve the graft and patient survival. 
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REVIEW OF LITERATURE 
 Prospective studies and analyses of registry data have shown that many 
variables affect renal allograft survival and lead to graft dysfunction. These variables 
can be immunogenic and nonimmunogenic. The factors    can be considered as donor, 
recipient, or donor cum recipient factors. Many of them contribute to the development 
of graft dysfunction. 
 Early allograft dysfunction refers to loss in the first 12 months; late 
dysfunction or loss to any time thereafter. This distinction is empirical but makes 
clinical sense. In the first 12 months, allograft loss or dysfunction is relatively 
common, because of technical complications such as graft thrombosis and because of 
severe rejection. After 12 months, the incidence is lower but remains stable over time.  
The causes of late allograft loss are also different and patient death is equivalent to 
allograft loss             
 On the basis of 3 to 4 years of follow-up, compared to hemo or peritoneal 
dialysis, transplantation reduced the risk of death overall by 68%.[1] Transplantation 
was particularly life saving in diabetic patients. 
 The principal causes of allograft loss in the first post-transplant year are acute 
rejection, thrombosis, primary nonfunction, and patient death. 
 The current adjusted 1-year survival probability for recipients of deceased 
donor allograft (first or subsequent transplant) is 91%, this rate has slowly but steadily 
improved over the past 25 years. The current adjusted 1-year survival probability for 
recipients of living donor allograft (first or subsequent transplant)is 95%.[2] These 
outcomes have also improved over the past 25 years. 
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 The longevity of patient and graft survival depends on donor, recipient and 
donor- recipient factors 
Donor Source: 
Deceased Versus Living Donor  
 The donor source is one of the most important predictors of short- and long-
term allograft outcomes. In general, living donor are superior to deceased donor 
allograft [3] [4]).  The better outcomes depends  on several factors like healthy living 
donors, the absence of brain death,  elective surgery, avoidance of ischemia-
reperfusion injury, high nephron mass and  shorter waiting time. Excellent results are 
now being demonstrated with living unrelated kidney transplantation in which HLA is 
not matching.[5] Allograft outcomes are superior with deceased donors with trauma as 
opposed to other  causes of brain death.[2] 
Donor Age  
 Kidneys from donors older than 50, and particularly 65, years of age have 
poorer outcomes. This effect is especially pronounced in deceased donor allograft. 
Allograft from older donors has low nephron mass because of the aging process and 
due to pre existing diseases like hypertension and atherosclerosis. Donor age younger 
than 5 years is also associated with poorer outcomes due to nephron under dosing. En 
bloc transplantation from donors aged 0 to 5 years significantly improves survival [6] 
Donor Sex  
 There is evidence that allograft from female donors have slightly poorer 
survival. [2] [102] due to  smaller renal mass and ethnicity differences  
  
 4
Donor Nephron Mass  
 Donor nephron mass is most important for longevity of graft survival. If there 
is a mismatch between donor nephron mass and recipient body mass index, it will 
lead to early chronic allograft nephropathy.  
Cold Ischemia Time  
 Prolonged cold ischemia time particularly more than 24 hrs  leads to delayed 
graft function and early CAN.  Cold ischemia time is very important in deceased 
donor transplant. 
Recipient Age 
 Allograft survival rates vary in extremes of ages particularly in age less than 
17 or older more than 65 yrs [2]. The common cause for graft loss is acute rejection, 
vessel thrombosis. In older age group graft loss is mainly due to death and not due to 
rejection 
Recipient Race  
 Black recipients generally have poorer deceased donor graft survival compare 
to other races.  
Recipient Gender   
 Female recipients had slightly better allograft survival than male recipients of 
deceased donor kidneys or HLA-identical kidneys recipients of living donor 
kidneys.[8this is mainly due to high  degree of sensitization to HLA ,non HLA 
antigen, pregnancy and  because of more blood transfusions related to menstruation. 
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Recipient Sensitization  
 Patients who are highly sensitized (PRA greater than 50%) generally have 
poorer early and late graft survival compared with nonsensitized recipients. This is 
mainly related to an increased incidence of complications in the early post-transplant 
period such as DGF and acute rejection. The principal reasons for sensitization are 
previous transplants, pregnancy, and blood transfusion. Thus, allograft survival is 
poorer in recipients of second or third transplants compared with recipients of a first 
transplant.[2] Highly sensitized patients are usually given more intensive 
immunosuppression. 
Recipient Immunosuppression  
 After invention of newer immunosuppressive agents like  CSA ,Tacro, MMF, 
improve the short term graft survival by reducing incidence of acute rejection. On the 
contrary, long term CNI use contributes to chronic allograft dysfunction by induction 
of chronic renal ischemia, and by promotion of systemic hypertension. Registry data 
analysis suggests that MMF improves long-term graft survival both by preventing 
overt acute rejection and by other mechanisms.[13]  
Recipient Compliance  
 Poor compliance with the immunosuppressive regimen greatly increases the 
risk of acute rejection and allograft loss. In one recent meta-analysis, a third of the 
allograft losses were linked to patient noncompliance.[10] 
Proteinuria  
 Proteinuria, even when modest, is associated with poorer allograft survival 
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ALLOGRAFT DYSFUNCTION  
 Allograft dysfunction analyzed under three time periods: immediate, early, 
and late post-transplant. 
Immediate Post-transplant Period (First Week)  
 Patients can be divided into three groups DGF, SGF, excellent graft function 
based on allograft function in the first post-transplant week. 
 DGF is usually defined as failure of the renal allograft to function immediately 
after transplant, and requires  few dialysis session.  
 Excellent allograft function implies normal graft function with  adequate urine 
output and rapidly falling plasma creatinine. 
 SGF defines a group of recipients with moderate early dysfunction. One 
definition is a plasma creatinine level of greater than 3 mg/dL and no dialysis within 1 
week of transplant. 
Delayed Graft Function  
 DGF is a clinical diagnosis.  Criteria for dialyzing patients post-transplant 
differ between centers. Recent United States Renal Database System (USRDS) data 
still show an approximate 22% incidence of DGF in deceased donor allograft.[2 the 
causes of DGF, are the following among them Ischemic acute tubular necrosis (ATN) 
is by far the most common cause   
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Causes of DGF in Renal Transplantation 
Prerenal 
Severe hypovolemia/hypotension 
Renal vessel thrombosis 
Intrarenal 
Ischemic ATN 
Hyperacute rejection 
Accelerated or acute rejection superimposed on ATN 
Acute cyclosporine/tacrolimus nephrotoxicity (± ATN) 
Postrenal 
 Urinary tract obstruction/leakage 
The diagnosis of the underlying cause of DGF is based on clinical, radiologic, 
and sometimes histologic findings.     
 Definitive diagnosis of the underlying cause requires allograft biopsy. The 
decision to do biopsy depends mainly on the duration of DGF and the likelihood of 
the underlying cause being ATN as opposed to a more allograft-threatening cause 
such as rejection. Specific treatment of DGF depends on the underlying cause  
Ischemic Acute Tubular Necrosis.  
 Ischemic ATN is the most common cause of DGF in deceased donor kidney 
recipients.   
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 There is no clinical or radiologic features unique to transplant ATN. The 
natural history of uncomplicated ATN is spontaneous resolution. Usually, 
improvements in urine output begin from 5 to 10 days after transplant, but ATN may 
persist for weeks. 
 Management of the patient during this period is supportive, including dialysis 
if needed and avoidance of fluid overload. . When hemodialysis is required, minimal 
anticoagulation should be used to reduce the risk of postsurgical bleeding. 
Intradialytic hypotension must be avoided during dialysis  
 Experimental animal models have demonstrated that ischemic ATN is 
associated with increased expression/production within the renal parenchyma of class 
I and II major histocompatibility complex (MHC) molecules, co stimulatory 
molecules, pro inflammatory cytokines and adhesion molecules, thereby predisposing 
to acute rejection  .[12].   Recent data from varies studies suggest that intra operative 
thymoglobulin shortens the duration of DGF, possibly by blockade of multiple 
receptors on human leukocytes.[16] 
Hyper acute Rejection.  
 Hyper acute rejection is now a rare cause of immediate non functioning of 
graft. It is caused by preformed recipient antibodies reacting with antigens on the 
endothelium of the allograft, activating the complement and coagulation cascades. 
These antibodies are usually directed against antigens of the ABO blood group system 
or against HLA class I antigens. Anti-HLA class I antibodies are formed in response 
to previous transplantation, blood transfusion, or pregnancy. The only effective 
treatment is transplant nephrectomy. Screening for recipient-donor ABO and class I 
HLA incompatibility have ensured the rarity of hyper acute rejection 
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Acute Cyclosporine or Tacrolimus Nephrotoxicity Superimposed on Acute 
Tubular Necrosis.  
 Cyclosporine or tacrolimus, especially in high doses, causes an acute 
reversible decrease in GFR by renal vasoconstriction, particularly of the afferent 
glomerular arteriole. These drug toxicities further exacerbate ischemic ATN.  
Vascular and Urologic Complications of Surgery.  
 Renal vessel thrombosis, urinary leaks, and obstruction are rarer but important 
causes of DGF. These complications may also cause allograft dysfunction in the early 
postoperative period  
Outcome and Significance of Delayed Graft Function  
 In most cases, recovery of renal function is sufficient to become independent 
of dialysis. There is no recovery in less than 5% of cases, resulting in primary 
nonfunction of graft . The majority of studies suggest that DGF has a negative impact 
on long-term renal allograft survival.[15]     
Early Post-transplant Period (First Six Months)  
 There is obviously some overlap in the causes of delayed and early allograft 
dysfunction. The following are the causes for early graft dysfunction 
Causes of Allograft Dysfunction in the Early Postoperative Period 
Prerenal 
Hypovolemia/hypotension 
Renal vessel thrombosis 
Drugs: ACE inhibitors, NSAIDs 
Transplant renal artery stenosis 
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Intrarenal 
Acute rejection 
Acute CNI nephrotoxicity 
CNI induced thrombotic microangiopathy 
Recurrence of primary disease 
Acute pyelonephritis 
Acute interstitial nephritis 
Postrenal 
Urinary tract obstruction/leakage 
Prerenal Dysfunction in the Early Post-transplant Period : 
Hypovolemia and Drugs  
 Hypovolemia may develop secondary to excessive diuresis from the 
transplanted kidney or from diarrhea. Diarrhea is a common adverse effect of the 
MMF plus tacrolimus combination.  Angiotensin-converting enzyme inhibitors (ACE-
Is) and nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in the early 
post-transplant period because of the risk of functional pre renal failure 
Renal Vessel Thrombosis  
 Transplant renal artery or renal vein thrombosis usually occurs in the first 72 
hours but may be delayed for up to 10 weeks. Acute vascular thrombosis is the most 
common cause of allograft loss in the first week.  
 Duplex studies show absent arterial and venous blood flow. Renography or 
magnetic resonance (MR) angiography shows absent perfusion of the transplanted 
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kidney in case of artery thrombosis and thrombus in case of venous thrombosis. 
Removal of the infarcted kidney is indicated in both the cases. 
Intrarenal Dysfunction in the Early Post-transplant Period: 
Acute Rejection  
 Most cases of acute rejection occur in the first 6 months, but this complication 
may occur at any time.  
 Definitive diagnosis requires biopsy, but when there is a high likelihood of 
uncomplicated acute cellular rejection (ACR), empiric treatment is sometimes 
instituted. Acute rejection is presumed to involve cellular and humoral immune 
mechanisms, but evidence of cell-mediated responses has traditionally predominated 
on most biopsies. 
Acute Cellular Rejection.  
 The Modified-Banff classification is a widely used schema for classifying 
rejection.  
Modified-Banff Classification of Renal Allograft Pathology 
1.  Normal 
2.  Antibody-mediated rejection 
Acute 
Type I: C4d+, ATN 
Type II: C4d+, capillaritis 
Type III: C4d+, arteritis 
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Chronic active 
 Glomerular double contours and/or peritubular capillary basement membrane 
multilayering and/or interstitial fibrosis/tubular atrophy and/or fibrous intimal 
thickening in arteries, C4d+ 
3.   Borderline changes (“suspicious” for acute rejection). Foci of mild tubulitis 
only. 
4.   T-cell mediated rejection 
 “Chronic allograft arteriopathy” (arterial intimal fibrosis with mononuclear 
cell infiltration in fibrosis, formation of neo-intima) 
5.   Interstitial fibrosis and tubular atrophy, no evidence of any specific etiology 
6.   Other: Changes not considered to be due to rejection 
 Focal infiltrates of mononuclear cells without endothelialitis or tubulitis may 
occur in the presence of stable allograft function and hence require no treatment. 
Conversely, histologic evidence of rejection can also be seen in the presence of stable 
allograft function, and there is evidence to support its treatment.[18] The presence of 
eosinophils in the infiltrate suggests severe rejection, but allergic interstitial nephritis 
should also be considered.  
 Uncomplicated ACR is generally treated with a short course of high-dose 
steroids. Typically, 500 to 1000 mg/day of methylprednisolone is given intravenously 
for 3 to 5 days. There is a 60% to 70% response rate to this regimen. After completion 
of pulse therapy, the maintenance oral steroid dose can be resumed immediately, 
although some centers prefer to taper back to the maintenance dose. An episode of 
acute rejection implies that prior immunosuppression has been inadequate. OKT3 and 
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the polyclonals are highly effective in treating first rejection episodes but because of 
cost and toxicity, these agents are usually reserved for steroid-resistant cases or when 
there is severe rejection on the initial biopsy. 
Steroid-resistant ACR, defined somewhat arbitrarily as failure of improvement 
in urine output or plasma creatinine within 5 days of starting pulse treatment, is 
usually treated with depleting antibodies. One randomized, controlled trial has shown 
rabbit thymoglobulin to be more effective than ATG as primary therapy for acute 
rejection[19]; thymoglobulin has also largely replaced OKT3 in this setting.[20] 
Acute Antibody-Mediated Rejection.  
Acute AMR is increasingly recognized as a cause of allograft dysfunction and 
is now seen in 12% to 37% of biopsies done for acute rejection. This probably reflects 
better diagnostic tools (in particular, the C4d stain and improvements in tissue 
typing[23]), more awareness of acute AMR, better prevention of ACR, and more 
transplantation across HLA or ABO incompatibilities.[24] Diagnosis of acute AMR 
requires allograft dysfunction and at least two of the following: (1) neutrophil 
polymorphs or mononuclear cells or thrombi in capillaries, (2) diffusely positive 
staining of peritubular capillaries for C4d, (3) serologic evidence of antibody against 
donor HLA or ABO antigens.[25] Acute AMR typically occurs early after 
transplantation but can also occur late, especially in the setting of reduced 
immunosuppression or noncompliance. Acute AMR may occur alone or with ACR. 
Until recently, the prognosis of acute AMR was considered poor. Now, good 
short- and medium-term outcomes have been reported with protocols that typically 
include the following: pulse steroids, tacrolimus, MMF, plasmapheresis, or high-dose 
IgG.[26] Rituximab is sometimes used as an adjunct in severe cases, although 
randomized controlled trials are lacking. 
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Acute Calcineurin Inhibitor Nephrotoxicity: 
The CNIs, especially in high doses, cause an acute reversible decrease in GFR 
by renal vasoconstriction, particularly of the afferent glomerular arteriole. This is 
manifested clinically as dose and blood concentration-dependent acute reversible 
increases in plasma creatinine. Because acute CNI nephrotoxicity is mainly 
vasomotor / prerenal, histologic changes in this setting may be unimpressive. 
Histology may show tubule cell vacuolization; more prolonged toxicity is associated 
with hyaline thickening of arterioles[27]; these changes are not specific. Acute CNI 
nephrotoxicity responds to dosage reduction. 
Acute Thrombotic Microangiopathy  
Acute TMA after renal transplantation is a rare but serious complication.[28] 
Causes include CNIs, OKT3, acute AMR [29] viral infections such as 
cytomegalorvirus (CMV) and recurrence of primary disease . The presence of 
hepatitis C and anticardiolipin antibodies increases the risk.[30] Onset is usually in the 
early post-transplant period. The classic laboratory findings are increasing plasma 
creatinine and lactate dehydrogenase levels, thrombocytopenia, falling hemoglobin 
level, schistocytosis. and low haptoglobin level. In severe cases, the long-term 
prognosis for the allograft is often poor. Early diagnosis of TMA is essential to 
salvage renal function. There are no controlled trials of therapy for TMA after 
transplant.  
Acute Allergic Interstitial Nephritis  
 Distinguishing acute allergic interstitial nephritis and ACR is very difficult. In 
fact, the pathogenesis is somewhat similar in both cases, involving mainly cell-
mediated immunity. Fever and rash after ingestion of a new drug favor the former. 
Polyomavirus infection must also be considered in the differential diagnosis. Both 
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acute allergic interstitial nephritis and ACR usually respond to steroids. SMX-TMP is 
probably the drug most likely implicated in causing allergic interstitial nephritis in 
renal transplant patients. 
Early Recurrence of Primary Disease  
Several renal diseases may recur early and cause acute allograft dysfunction.  
Among them   primary focal segmental glomerulosclerosis, antiglomerular basement 
membrane disease are most common.  
Postrenal  Dysfunction in the Early Post-transplant Period : 
The incidence of serious early post-transplant urologic complications has 
decreased significantly over the last 20 years. However, post renal causes must always 
be considered in the differential diagnosis of acute allograft dysfunction. The 
following are post renal cause for dysfunction 
1. Urine leak 
2. Urinary tract obstruction 
Late Post-transplant Period  
Late Acute Allograft Dysfunction  
The causes and evaluation of late (>6 months post-transplant) acute allograft 
dysfunction are broadly similar to those of early acute dysfunction. Acute prerenal 
failure may occur at any time, and the causes are similar to those seen with native 
kidneys, such as shock syndromes and ACE-I or NSAID hemodynamic effects. 
Urinary tract obstruction must also be considered in the differential diagnosis. 
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Late Acute Rejection  
With standard immunosuppressive protocols, acute rejection is uncommon 
after the first 6 months. Late acute rejection can occur while tapering or withdrawing 
immunosuppression.  Therefore, plasma creatinine must be carefully monitored when 
these drugs are stopped. Late acute rejection usually has a large cellular component, 
but there may be superimposed acute AMR, C4d staining should be routinely 
performed in all the cases 
Late Acute Calcineurin Inhibitor Nephrotoxicity  
Although lower doses of CNIs are generally prescribed after the first 6 to 12 
months, acute CNI toxicity may occur at any time after transplant. Intake of 
medications that impair metabolism of the CNIs may induce acute deterioration in 
renal function, but this should be reversible with appropriate drug adjustment.  
Transplant Renal Artery Stenosis  
Transplant renal artery stenosis can arise at any time after transplantation. The 
reported incidence varies widely.[30] Luminal narrowing of more than 70% is probably 
required to render a stenosis functionally significant. The stenosis may occur in the 
donor or recipient artery or at the anastomotic site. Stenosis of the recipient iliac 
artery may also compromise renal arterial flow. The causes for stenosis are operative 
trauma to these vessels, atherosclerosis of the recipient vessels, and   immunological 
factors. The “gold standard” for diagnosis is renal angiography, but this is invasive. 
Both MR angiography and duplex sonography  are highly sensitive in diagnosing 
transplant renal artery stenosis and are adequate screening tests.[30] MR angiography 
has the advantage of better imaging the iliac arteries and identifying anatomy before 
angioplasty. Mild cases are often treated conservatively with antihypertensives, 
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aspirin. Percutaneous transluminal angioplasty (PTA) has been the treatment of 
choice for more severe cases.  
Infections Causing Late Acute Allograft Dysfunction : 
Human Polyomavirus Infection : 
The polyomaviruses are DNA viruses, the best known of which are the BK 
virus, JC virus, and SV40 virus.  Over the last 10 years, BK virus has been 
increasingly recognized as an important cause of renal allograft dysfunction and loss.  
Replication of BK virus, with shedding of infected uroepithelial cells (decoy 
cells) into the urine occurs in more than one third of renal transplant recipients.[31] The 
clinical features associated with such replication include  acute and chronic allograft 
dysfunction, and hemorrhagic cystitis. The allograft dysfunction is usually due to 
interstitial nephritis.Diagnosis of polyomavirus interstitial nephritis obviously requires 
allograft biopsy. The presence of intranuclear tubule cell inclusions by light 
microscopy should raise suspicion but diagnosis is confirmed by 
immunohistochemistry. It is difficult to distinguish viral infection alone from 
infection plus superimposed rejection. 
The most important therapy for established BK virus nephritis is major 
reduction in immunosuppression to augment host mechanisms of viral clearance. 
Other therapies that have been reported in small series to be effective include 
leflunomide, low-dose cidofovir , IgG, and fluoroquinolones.[32] 
Hepatitis C: 
The management of progressive hepatitis C virus (HCV) disease in renal 
transplant recipients remains unsatisfactory. Reduction in immunosuppression is the 
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first step, and this obviously increases the risk of rejection. Treatment with interferon-
alfa may induce temporary remission but the rate of relapse is high. Furthermore, the 
risk of provoking acute allograft dysfunction or loss with this drug via rejection or 
other mechanisms is high.[33] 
Both membranoproliferative glomerulonephritis (MPGN) and membranous 
nephropathy are more commonly seen in HCV-positive compared with HCV-negative 
renal transplant recipients.  
Drug and Radiocontrast Nephrotoxicity  
A variety of drugs can cause acute dysfunction of the renal allograft. In many 
cases, the offending agent are aminoglycoside , amphotericin, NSAID, ACE or ARBs 
in the presence of transplant renal artey stenosis, statins and radiocontrast agents. 
However, a number of drug-related nephrotoxic effects are more common in the 
setting of transplantation  Many of these effects are due to interaction with the CNIs. 
Diltiazem, verapamil, ketoconazole, and the macrolide antibiotics, particularly 
erythromycin, impair CNI metabolism and may lead to acute CNI nephrotoxicity 
unless there is concomitant dose reduction of the CNI. There are reports implicating 
the newer antidepressants and some of the antiretroviral drugs in this regard.[34] High-
dose SMX-TMP may cause an acute increase in plasma creatinine by inhibiting tubule 
secretion of creatinine. Rarely, SMX-TMP can provoke allergic interstitial nephritis; 
this is treated by cessation of the drug and administering high-dose steroids. 
Late Allograft Dysfunction and Late Allograft Loss (>3 to 6 Months) : 
 By far, the most important cause of allograft dysfunction after the first 6 to 12 
months is chronic allograft nephropathy (CAN). The causes of late dysfunction areas 
follows. The main causes of allograft loss are patient death, CAN, late acute 
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rejection/non-compliance, and recurrent disease. The following are the causes of late 
allograft dysfunction  
Prerenal 
Transplant renal artery stenosis 
Intrarenal 
Chronic allograft nephropathy 
CNI toxicity 
Chronic rejection (cellular or antibody mediated or both) 
Polyoma virus nephropathy 
Recurrence of primary disease / new disease 
Postrenal 
Urinary tract obstruction 
Chronic Allograft Nephropathy: 
After censoring for death, CAN is the most frequent and important cause of 
long-term allograft loss. Halloran and colleagues [35] have defined CAN as a “state of 
impaired renal allograft after excluding other causes like acute rejection, overt drug 
toxicity, and recurrent or de novo diseases.  
Histopathologic changes are seen in the tubulointerstitium, vessels, and 
glomeruli. These changes are not unique to CAN but include (1) atrophy and fibrosis 
of the tubulointerstitium, (2) fibrointimal thickening of arterial walls, (3) transplant 
glomerulopathy (thickening and double contouring of capillary walls and increased 
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mesangial matrix).[36] The degree of damage of the tubulointerstitium determines the 
stage of CAN . 
The pathogenesis of CAN remains incompletely understood. Alloantigen-
dependent and alloantigen-independent factors are considered to be important. Several 
of these factors probably interact in all patients with CAN. There is accumulating 
evidence that the humoral immune system contributes to the development of CAN 
and that chronic AMR is particularly associated with transplant glomerulopathy. [38] 
[36] [37].                                
 Typical clinical features are hypertension, proteinuria, and falling GFR. Onset 
is rarely less than 6 months after transplant.. Proteinuria is usually subnephrotic range 
but may be severe enough to cause nephrotic syndrome. Severe proteinuria and 
inadequately controlled hypertension are associated with more rapid deterioration in 
renal function. 
 Renal ultrasound should be performed to rule out an obstructive cause. If there 
is suspicion of renal artery stenosis, further testing is indicated. Allograft biopsy helps 
characterize the predominant form of damage. [39] [40] 
 Treatment options are very limited. If there is histologic evidence of a 
component of acute rejection, pulse steroids are often used. If the clinical and 
histologic picture suggests a significant component of chronic CNI nephrotoxicity, the 
CNI dosage can be reduced. Alternative agents such as MMF or sirolimus can be 
substituted,[41] but patients should be watch closely for late acute rejection. Sirolimus 
should probably be avoided in those with proteinuria or GFR of less than 40 
mL/min.[42] 
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 Hypertension and hyperlipidemia should be rigorously controlled. There are 
no randomized controlled trials in CAN but ACE-I or angiotensin receptor blockers 
are often used.  
Late Recurrence of Primary Disease : 
 The incidence of late recurrence is difficult to estimate: the original cause of 
ESRD is often unknown, transplant kidney biopsies are not always performed; and 
most relevant studies are small and retrospective with variable follow-up periods. In 
one large study of patients who underwent transplantation after developing ESRD 
from glomerulonephritis, recurrence was the third most frequent cause of graft loss at 
10 years [44]   . the following recurs in the graft  
IgA Glomerulonephritis : recurrence more common  
Lupus Nephritis 
Membranoproliferative Glomerulonephritis 
Membranous Nephropathy 
Diabetic Nephropathy : 
Measures to improve renal allograft survival 
 Increased living kidney donation : both related and nonrelated. 
 Preemptive transplantation in live kidney transplantation. 
 Increased donation from younger, previously healthy deceased donors. 
 Preferential matching of younger deceased donors with younger recipients. 
 Zero mismatching of HLA antigens 
 Improved organ preservation 
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 Reduced cold ischemia time 
 Nephron dosing (e.g. matching of donor recipient sex, body mass index) 
 Calcineurin inhibitor sparing immunosuppressive protocols. 
 Angiotensin converting enzyme inhibitors, angiotensin receptor blockers. 
 Aggressive control of hyperlipidemia, hypertension. 
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MATERIALS AND METHODS 
Study place   : Stanley Medical College 
     Nephrology Department, Chennai 
Study period   : From October 2009 to march 2011 
Study design   : Prospective study 
Study population  : All the patients who have undergone transplant 
     at Stanley Medical College and on regular  
     follow-up in outpatient Department of  
     nephrology were enrolled in this study 
 In our department we are regularly doing renal transplants since 1998. We do 
live related transplants between first degree relatives, spousal, cadaver transplants 
(approximately 40 per year). Since we cater to economically very poor patients we do 
hemodialysis, transplant surgery and immunosuppressive treatment free of cost.  
All the recipient enrolled in the study are in different period of follow up, 
depending the date of transplant, follow-up period varying from 3 months to 3 yrs       
Depending on the post transplant period they are followed once a week or 
once in two weeks.  
Raised creatinine > 25% from the baseline or increase of 0.3 – 0.5 mg from 
the baseline creatinine was considered as criteria for graft dysfunction. All patients 
with graft dysfunction patients were subjected to graft biopsy after ruling out other 
causes for graft dysfunction.     
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For the present study I have followed up all post transplant recipients who 
have normal creatinine with graft dysfunction and analyzed etiology and factors 
contributing to graft dysfunction by comparing with normal graft function recipients 
DONOR EVAUVATION 
LIVE RELATED DONOR. 
 Only First degree relatives were selected as a donor.  HLA ABC matching 
done to ascertain relationship 
If HLA is not matching, in case of siblings, HLA from parents were taken to 
ascertain relationship,                   
In case of spousal donor relationship approval by authorization committee 
Obtained 
Donor Selection Criteria: 
1. Age criteria – donors  more than 20 yrs and less than 60 yrs are selected 
2. The donor should be  either parents or offspring or sibling of the recipient  
3. Spousal donors are considered for recipients who do not have medically fit  
donor / willing first degree relatives 
4. Donors founds to have  DM & SHT during screening are rejected 
Donors are thoroughly evaluated by history, clinical, biochemical and 
imaging modalities 
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All donors underwent the following investigation                         
                         GTT, HbA1c 
                         Thyroid function test, 
                         Liver function test 
                         Complete blood count 
                         Renal function test   
                         Hepatitis viral serology (HbsAg, Anti HCV) 
                         HIV ELISA 
 The donor should be having perfect health prior to being declared fit for 
transplantation. 
Donor’s renal status assessed by: 
                            USG abdomen 
                            Urine analysis 
                            24 hrs urine protein 
                             Radio nucleotide (DTPA) scanning for split GFR   
                             Computerized tomography renal angiogram and  IVU  
 Male Donors with more than 40 yrs of age are subjected uroflowometry 
studies   CMV screening is not done routinely for donors. 
 Donors are explained in detail about the procedure of transplantation and 
possible risks 
 A written informed consent is obtained from the donor and relatives of donor 
and donors guardians. 
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CADAVER DONOR: 
 Brain dead donors mostly are road traffic accident victims  
 Donors are screened for diabetes, hypertension, underlying renal disease prior 
to   harvesting 
 At present no extended donor criteria patients are included 
 All cadaver donors screened for HbsAg, Anti HCV and HIV serology 
 Donor’s age ranged from 15 – 60 years   
 Donor kidneys were received from various hospitals in Tamil Nadu and also 
from    our own   hospital.  
 All cadaver grafts were perfuse with HTK solution (Custodial solution) 
 Custodial (HTK) solution (in mmol/L) 
• Sodium chloride    15.0 
• Potassium chloride      9.0 
• Potassium hydrogen 2-ketoglutarate    1.0 
• Magnesium chloride      4.0 
• Histidine Hcl        18.0 
• Histidine              180.0 
• Tryptophan      2.0 
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• Mannitol     30.0 
• Calcium chloride             0.015 
Kidneys are stored in ice box with three bag technique during transportation 
RECIPIENTS  
LIVE donor recipient 
Recipient of less than 60 years of age are selected 
The cause of NKD, is identifiable in less than 50% of cases 
All recipients undergo viral screening for HBV, HCV and HIV 
 
 One recipient acquired HbsAg positivity during hemodialysis. He underwent 
HBV DNA by quantitative PCR, and liver function test and started on lamivudine 
.after 6 months of lamivudine therapy he was transplanted with normal liver function 
test with normal echo texture. 
Two recipient acquired HCV positivity during HD. both of them were 
maintained on hemodialysis and none of them received interferon therapy (due to 
financial constraint). Both of them underwent transplant after six   months of 
maintenance hemodialysis with normal liver function test 
 All patients undergo complete cardiac, gastroenterology, ENT, dental, 
dermatological, psychiatric, ophthalmological and urological evaluation 
 All recipients are vaccinated for HBV 
 Voiding cystourethrograms, uroflometry were done to assess the lower urinary 
tract abnormalities whenever required 
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 Donor and recipient tissue cross match done by lymphocytotoxic method 
within 72 hours before Transplantation and only those with  cross match 15 % or less 
were  taken for transplant surgery. For live related transplant cross match was done 
during the preliminary stage itself. 
 Both cadaver and live related donor recipients undergo Doppler of aorta iliac 
vessels prior to Transplant to assess vessel status  
All recipient are maintained only on hemodialysis prior to transplantation 
All patients are given triple immunosuppression with cyclosporine / Tacrolimus, 
azathioprine / MMF, and prednisolone.  
Spousal and cadaver transplant recipient started on Tacrolimus, MMF and 
prednisone 
CSA / AZA regimen started on those who are all underwent transplant prior to 
2008. 
Now all live donor recipient started on Tacrolimus, azathioprine and prednisone 
based regimen 
No induction therapy is given for cadaver and spousal transplant.  
None of the recipients underwent de sensitization protocols    
CADAVER DONOR RECIPIENT 
Those who are not having prospective live related or spousal donor are included in 
the cadaver list  
All registered recipients are on regular follow up  
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Human Leukocyte Antigen (HLA) and Panel Reactive Antibody (PRA) were not 
done for any of our cadaver recipients and cadaver donors. 
Recipients undergo regular serology screening during follow up 
 DECEASED DONOR GRAFT ALLOCATION POLICY 
 A separate cadaver waiting list for each blood group of potential recipients is 
maintained according to their date of induction into hemodialysis.  This seniority list 
is available online and it is supervised by transplant committee formed by the 
Government of Tamil Nadu. 
 Selection of recipients is based on their seniority in cadaver waiting list 
 Donor and recipient tissue cross match done  by lymphocytotoxic method 
before transplant and cross match less than 15 % were alone taken for 
transplant surgery 
 Transplant surgery was done alternatively by two teams of Urologists. 
Recipients with co morbid conditions are temporarily excluded   from the list and 
included again once they recover. 
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PROCEDURE 
Pre operative treatment 
 All recipients were given Hemodialysis pre operatively.  They were started on 
immunosuppression prior to surgery as below. 
 Day before Surgery 4 p.m. 0 POD (4 a.m.) 
T.Tacrolimus 0.066 mg/kg 0.066 mg/kg 
T.MMF 500 mg 500 mg 
T.Prednisone 0.5 mg/kg 0.5 mg/kg 
  
Operative Technique 
 Grafts are placed in the right iliac fossa after creating renal bed except in 
second transplant.  Anastomosis of the renal vessels to the iliac vessels was performed 
as follows. 
 Renal artery to internal iliac artery (except one patient) – end to end.   
Renal vein to external iliac vein – end to side.   
 Ureter anastomosed to bladder obliquely by creating neocystostomy in the 
region of the trigone.  DJ stents were kept if required. 
 During anastomosis of graft vessels, methyl prednisone 1 g was given as I.V. 
infusion. 
Post operative treatment 
 Fluids (0.9% NS) were given according to their urine output.  
Immunosuppression was given as follows: 
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 T.Tacrolimus 0.06 mg/kg twice daily (Target tacrolimus level 10 – 12 ng/ml 
subsequently reduced to 5ng/ml by 6 months) 
T.MMF 500 mg twice / thrice daily 
T.Prednisone 0.5 mg od 
 
 Tacrolimus levels were assessed on 5th to 7th POD for all recipients.  USG 
and Doppler of graft vessels are assessed on or before 7th POD.  Recipients urinary 
Foley’s Catheter is removed on 7th POD.  Drainage tube was removed if drainage 
fluid is less than 50 ml.  DJ stent if inserted is removed on 4th post operative week. 
After 14 days, recipients are discharged and they are seen as outpatient at 
regular intervals as below: 
Twice a week for the first month  
Weekly once for next two months,  
Fortnightly for first one year  
And monthly for life long.  
 
  During each visit, patient’s condition, renal function test and complete blood 
count were analyzed and other tests as and when required like (Cyclosporine, 
Tacrolimus levels) 
Post operative drugs including immunosuppressant are given free of cost and 
all  investigations are done at no cost.    
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                                             METHODS 
Prospective Study 
All renal transplant recipients on regular follow up are included - September 
2009 to march 2011 
 Those who died and those who are in irregular follow up during the period of 
study are excluded from the study 
All the patient having graft dysfunction underwent renal biopsy 
The following parameters of both donor and recipient of graft dysfunction 
were taken up and analyzed with normal graft function 
Donor Parameters 
1. Age 
2.  Sex 
3. Blood Group 
4. Left or right  kidney 
5. Number of donor renal arteries and donor renal veins 
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Recipient Parameters 
1. Age 
2. Sex 
3. Group 
4. Months of hemodialysis 
5. HLA and CROSSMATCH 
6. Warm ischemic time – in case of live donor 
7. Cold ischemic time  
8. Intra operative events 
9. Day one urine output 
10. Day one creatinine 
11. Time to reach creatinine 1.2 
12. Discharge creatinine  
13. Type of immunosuppressant 
14. New onset of diabetes after transplant (NODAT) 
15. polycythemia 
All the data are collected in the master sheet and statistically analyzed 
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EXCLUSION CRITERIA 
1. Patients who are all died during the follow up period were excluded from the 
study. 
2. Those who are all an irregular follow up during the study period were also 
excluded from the study. 
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RESULTS 
 Totally 155 recipients are on regular follow up in our department from the 
period October 2009 to march 2011.  
Patients who died in that period and those who are on irregular follow up are 
excluded from the study 
Total patients are divided into two study groups (normal and graft dysfunction 
based on graft functioning) 
Graft dysfunction is defined as a raise in creatinine more than 25% from the 
baseline or 0.3 to 0.5 mg raise from the discharge creatinine  
89 recipients had normal graft function and 66 developed grafts dysfunction 
during the follow up period for which no other cause was found.  
All with graft dysfunction underwent biopsy if creatinine does not come down 
soon and if here is no clear cut cause. 
The following parameters are compared between two groups 
DEMOGRAPHIC DATA 
Among the 155 recipients, live donor transplant is 114, spousal transplant is 6,     
cadaver transplant is 35 
Among the 155 recipients 123 were male, 32 were female. Predominantly 
male population  
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                                                               Kidney Function 
Group Total 
Normal Dysfunction 
N % N % N % 
89 100.0 66 100.0 155 100.0 
 
DGF AND SGF Vs GRAFT FUNCTION 
DELAYED GRAFT FUNCTION: required hemodialysis in post operative period  
SLOW GRAFT FUNCTION         :  a group of recipients with is a plasma creatinine 
       level of greater than 3 mg/dL and no dialysis 
     within 1 week of transplant 
 Group Total 
Normal Dysfunction 
N % N % N % 
Type DGF 7 58.3 0 .0 7 46.7
SGF 5 41.7 3 100.0 8 53.3
Total 12 100.0 3 100.0 15 100.0
 
RESULTS 
     155 RECIPIENTS ARE INCLUDED IN THE STUDY 
     89 HAD NORMAL FUNCTION GRAFT 
     66 DEVELOPED DYSFUNCTION 
     DELAYED GRAFT FUNCTION –   7 developed DGF. All were cadaver  
                                                  recipie   
    12 HAD SLOW GRAFT FUNCTION     
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24 hrs protein (mg)  
 24 hr protein group N % 
< 500 7 10.9 
501 – 1500 43 67.2 
> 1500 16 21.9 
Total 66 100.0 
 
Biopsy Creatinine group 
 
Biopsy creatinine group N % 
< 1.50 3 4.5 
1.51 - 2.00 42 63.6 
> 2.00 21 31.8 
Total  66 100.0 
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Month  vs  biopsy 
Month Group  N % 
1 month 4 6.3 
2 - 6 months 18 27.0 
7 - 12 months 18 28.6 
> 12 months 26 38.1 
Total 66 100.0 
 
Recipients with graft dysfunction underwent 24 hrs urinary protein quantification  
Most of the recipient in the range of 500 to1500 mg 
Most of those with graft dysfunction had creatinine of 1.5 to 2.0  
 Most of the recipient underwent biopsy one year after transplant   
ETIOLOGY OF GRAFT DYSFUNCTION 
Parameter N % 
Anti body mediated rejection 2 1.3 
Actute cellular rejection 13 8.4 
Infection 2 1.3 
Acute tubular necrosis 9 5.8 
Thrombotic microangiopathy 6 3.9 
Chronic allograft nephropathy 28 18.1 
Drug Toxic 6 3.9 
Transplant renal artery stenosis 1 0.6 
Recurrence (IGA) 3 1.9 
 
All 66 recipients who had dysfunction underwent renal biopsy 
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DONOR AGE 
 Group N Mean Std. Deviation P - Value 
donor 
 age 
Normal 89 39.57 11.801 0.005
Dysfunction 66 44.29 8.747 
 
CADAVER AND LIVE DONOR SEPARATE 
Kidney donor Group N Mean Std. Deviation P - Value
Cadaver donor 
 age 
Normal 28 32.14 14.018 0.426
Dysfunction 7 36.71 10.259 
Live donor 
 age 
Normal 61 42.98 8.846 
Dysfunction 59 45.19 8.193 0.160
 
Results 
 Donor age significantly affects the graft dysfunction p value .005  
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DONOR SEX 
 
Group Total 
P  
Value  
Normal Dysfunction 
N % 
0.043 
N % N % 
Donor 
 sex 
Male 33 37.1 19 28.8 52 33.5 
Female 56 62.9 47 71.2 103 66.5 
Total 89 100.0 66 100.0 155 100.0 
 
DONOR RELATIONSHIP 
 Group Total 
Normal Dysfunction 
N % N % N % 
Relation Cadaver 28 31.5 7 10.6 35 22.6
Father 4 4.5 7 10.6 11 7.1
Mother 37 41.6 31 47.0 68 43.9
Brother 7 7.9 6 9.1 13 8.4
Sister 9 10.1 12 18.2 21 13.5
Spouse 4 4.5 2 3.0 6 3.9
Aunt what 
match 0 .0 1 1.5 1 .6
Total 89 100.0 66 100.0 155 100.0
 
RESULS  
Most of live donors were females 
Association of female donors with graft dysfunction is statistically significant. Likely 
because of smaller nephron mass  
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Donor Blood group 
 Group Total 
P - Value 
Normal Dysfunction N % 
 N % N %
Blood 
Group 
A 17 19.1 16 24.2 33 21.3 
0.233
B 29 32.6 29 43.9 58 37.4 
AB 4 4.5 2 3.0 6 3.9 
O 39 43.8 19 28.8 58 37.4 
Total 89 100.0 66 100.0 155 100.0 
 
Results  
Dysfunction group - B positive is more common blood group 
Association of blood group is not statistically significant between two groups  
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 KIDNEY SIDE vs GRAFT FUNCTION 
 Group Total 
Normal Dysfunction 
N % N % N % 
Side Left 75 53.6 65 46.4 140 100.0
Right 14 93.3 1 6.7 15 100.0
Total 89 57.4 66 42.6 155 100.0
 
Result  
Left side preferred more than right  
No significant association of side of kidney with graft function  
NUMBER OF BLOOD VESSEL VS GRAFT FUNCTION 
 Group Total  
P - Value
Normal Dysfunction 
N % N % N % 
vessel  
Involved 
Single 79 88.8 63 95.5 142 91.6 
0.234 
Double 9 10.1 2 3.0 11 7.1 
Triple 1 1.1 1 1.5 2 1.3 
Total 89 100.0 66 100.0 155 100.0 
 
Results  
142 grafts had single renal vessel 
Association between number of blood vessels with graft function   -  statistically not 
significant. 
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RECIPIENT AGE Vs GRAFT FUNCTION 
 Group N Mean Std. Deviation P - Value 
Age Normal 89 30.42 8.689 0.944 
Dysfunction 66 30.52 8.571  
 
 Group Total 
Normal Dysfunction 
N % N % N % 
Age Group 1 <= 35 yrs 70 78.7 51 77.3 121 78.1 
>35 yrs 19 21.3 15 22.7 34 21.9 
Total 89 100.0 66 100.0 155 100.0 
 
RESULT 
Recipient age difference between two groups   -   not significant P value 0.94 
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GENDER DIFFERENCE 
 Group Total P - 
Value 
Normal Dysfunction 
N 
% 
79.4 N % N % 
Gender Male 64 71.9 59 89.4 123  0.008 
Female 25 28.1 7 10.6 32 20.6 
Total 89 100.0 66 100.0 155 100.0 
 
GENDER DIFFERENCE BETWEEN CADVER AND LIVE 
Relationship with donor 
Group Total P - 
Value 
Normal Dysfunction
  N % N % 
Cadaver Gender Male 20 71.4 7 100.0  77.1 0.107 
Female 8 28.6 0 .0 8 22.9 
Total 28 100.0 7 100.0 35 100.0 
Others Gender Male 
40 70.2 50 87.7 90 
 
78.9 
0.022 
Female 17 29.8 7 12.3 24 21.1 
Total 57 100.0 57 100.0 114 100.0 
 
RESULT 
Among the Recipient most were males 
 Difference between two groups   -    significant P value 0.008 
Further sub group analysis done between cadaver and live recipient 
Among the live – male recipients had more dysfunction, significant P value 0.02 
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RECIPIENT BLOOD GROUP Vs GRAFT FUNCTION 
 Group Total  
Normal Dysfunction 
N % 
P - 
Value N % N % 
Blood Group A 17 19.1 16 24.2 33 21.3 
0.400 
B 31 34.8 28 42.4 59 38.1 
AB 5 5.6 4 6.1 9 5.8 
O 36 40.4 18 27.3 54 34.8 
Total 89 100.0 66 100.0 155 100.0 
 
RESULT 
B group recipient had more graft dysfunction 
Influence of blood group over dysfunction not significant P value 0.40  
Difference between two groups   -  not  significant P value 0.08 
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CAUSES OF NKD 
  N Col % 
Polycystic kidneys 2 1.3 
Diabetic nephropathy 2 1.2 
Focal segmental 
glomerulosclerosis 3 1.9 
 Global sclerosis 2 1.2 
IGA 14 9.0 
Ischemic glomerulo 
nephritis 4 2.5 
Mesangio proliferative 
glomerulo nephritis 2 1.3 
Reflux nephropathy 4 2.5 
Systemic lupus 
erythemetaosis 2 1.3 
Total 35 100.0 
 
Results 
Among them 35 had proven cause of native kidney disease 
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Duration of hemodialysis (months) vs GRAFT FUNCTION 
 Group N Mean Std. Deviation P – Value 
mhd(mon) Normal 89 9.06 8.658 0.081
Dysfunction 66 6.88 6.788 
 
 HLA Vs DYSFUNCTION 
 Group Total  
P – Value
0.012 
 
Normal Dysfunction
N 
% 
 N % N % 
HLA TYPE Not done 32 36.0 10 15.2 42 27.1 
HLA 2 54 60.7 51 77.3 105 67.7 
Full Match 3 3.4 5 7.6 8 5.2 
Total 89 100.0 66 100.0 155 100.0 
 
RESULTS 
 Number of months on hemodialysis is not statistically significant between the 
groups. 
 HLA     - (P value 0.012) ,   statistically significant to predict dysfunction  
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CROSS MATCH ( INTIAL) VS GRAFT FUNCTION 
 Group Total  
 
 
  P – Value
     0.580 
 
Normal Dysfunction 
N % N % N % 
CROSS 
MATCH 
intial 
5 19 31.1 17 28.8 36 30.0 
10 42 68.9 41 69.5 84 69.2 
Total 61 100.0 59 100.0 120 100.0 
 
CROSS MATCH FINAL VS GRAFT FUNCTION 
 Group Total  
 
  P – Value
     0.09 
 
Normal Dysfunction 
N % N % N % 
 CROSS 
MATCH 
FINALl 
5% 14 15.7 10 15.2 24 15.5 
10% 61 68.5 55 83.3 116 74.8 
15% 14 15.7 1 1.5 15 9.7 
Total 89 100.0 66 100.0 155 100.0 
 
RESULTS 
Intial cross match done only in live donor transplant – not significant 
Final cross match done in all cases – not significant to predict graft dysfunction P 
value 0.09 
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COLD ISCHEMIC TIME (MINUTES) VS GRAFT FUNCTION 
Kidney donor Group N Mean Std. Deviation P - Value 
Cadaver CIT Normal 28 466.07 174.639 0.520
Dysfunction 7 514.29 179.523 
Live CIT Normal 61 55.07 8.479 0.496
Dysfunction 59 54.10 6.855 
 
RESULTS 
In view of prolonged cold ischemic time in cadaver transplants , sub group analysis 
were done to   know the statistical significance  
Cadaver donor prolonged cold ischemic time mean   514minutes compare to live 54 
minutes 
The association of cold ischemia time with graft dysfunction is not statistically 
significant 
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CREATININE IN FIRST POST OPERATIVE DAY VS GRAFT FUNCTION 
 Group N Mean Std. Deviation P – Value 
cr 1st pod Normal 89 2.792 1.4746 0.282
Dysfunction 66 3.232 .8422
 
SUBGROUP ANALYSIS BETWEEN CADAVER AND LIVE 
Kidney donor Group N Mean Std. Deviation P - Value 
Cadaver cr 1st pod Normal 28 3.029 1.9903 0.090
Dysfunction 7 4.287 .8139 
Live cr 1st pod Normal 61 2.362 .8997 0.227
Dysfunction 59 2.556 .8459 
 
RESULT 
Day one creatinine does not show statistical significant between groups 
Subgroup analysis between groups also not significant 
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DAYS TAKEN TO REACH CREATININE 1.2 
 Group N Mean Std. Deviation P – Value 
cr1.2(day) Normal 88 6.82 8.039 0.045
Dysfunction 66 8.94 2.887
 
Kidney donor Group N Mean 
Std. 
Deviation P – Value
Cadaver cr1.2(day) Normal 28 6.61 12.066 0.452
Dysfunction 7 8.00 6.000 
Live cr1.2(day) Normal 60 4.58 3.567 0.990
Dysfunction 59 4.58 2.086 
 
RESULT 
Days after transplant creatinine reaches 1.2 was taken up for study 
Statistically significant association between groups P value 0.04  
Sub group analysis showed between cadavers and lives not statistically significant 
  
 52
DISCHARGE CREATININE VS GRAFT DYSFUNCTION 
 Group N Mean Std. Deviation P - Value 
dis cr Normal 89 1.113 0.1978 0.505
Dysfunction 66 1.135 0.1957
 
SUBGROUP ANALYSIS BETWEEN CADAVER VS LIVE  
Kidney donor Group N Mean Std. Deviation P - Value 
Cadaver dis cr Normal 28 1.186 .2649 0.786
Dysfunction 7 1.157 .1397 
Live dis cr Normal 61 1.080 .1492 0.112
Dysfunction 59 1.132 .2021 
 
RESULT 
Discharge creatinine - not statistically significant between the groups P value 0.50 
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DAY ONE URINE OUTPUT VS GRAFT DYSFUNCTION 
 Group N Mean Std. Deviation P – Value 
Urine 
output 
Normal 89 9851.69 5975.618 0.155
Dysfunction 66 8285 17836.890
 
SUBGROUP ANALYSIS  
Kidney donor Group N Mean Std. Deviation P - Value 
Cadaver Urine out 
put 
Normal 28 8043.21 5568.931 0.584
Dysfunction 7 5485.71 8342.397 
Live Urine out 
put 
Normal 61 13630 5342.301 0.475
Dysfunction 59 11500 18590.618 
 
RESULT 
Urine output in first postoperative day – not significant between groups 
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Treatment drug details 
 csa+aza csa+mmf tac+aza tac+mmf Total 
csa+aza 62 11 5 2 80 
csa+mmf 11 5 1 0 17 
tac+aza 5 1 13 2 21 
tac+mmf 2 0 2 42 46 
Total 80 17 21 46  
 
CSA vs graft function drug 
 
Normal Dysfunction Total  
 
P  
Value 
 
<0.001
N % n % n  % 
CSA + 
Yes 43 48.3 54 81.8 97 62.6 
No 46 51.7 12 18.2 58 37.4 
Total 89 100.0 66 100.0 155 100.0 
 
RESULT  
Most of the recipient on CSA based regimen.  
Compare to Tacrolimus, cyclosporine group had more number of graft dysfunction. P 
value 0.001 
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NEW ONSET OF DIABETES AFTER TRANSPLANT(NODAT) vs GRAFT 
FUNCTION 
 Group N Mean Std. Dev 
P – Value 
0.730 
NODAT 
Normal 27 6.96 10.078 
Dysfunction 24 8.08 12.954 
 
NODAT VS DRUGS 
CSA or TAC Group N Mean Std. Dev P - Value 
CSA + 
 
NODAT 
Normal 9 14.22 15.123 0.555 
Dysfunction 12 10.00 16.481  
TAC + 
 
NODAT 
 Normal 15 3.47 2.416 0.982 
Dysfunction 9 3.44 2.128  
 
RESULT 
NODAT - influence of NODAT over graft dysfunction is not significant   
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POLYCYTHEMIA VS GRAFT FUNCTION 
 Group N Mean Std. Dev P - Value 
Polycythemia 
Normal 14 8.29 5.030 0.597 
Dysfunction 12 7.08 6.403  
 
SUBGROUP ANALYSIS OF TACROLIMUS VS   CYCLOSPORIN  
CSA or TAC Group N Mean Std. Dev P - Value 
CSA + Polycythemia 
Normal 5 12.00 7.036 0.556 
Dysfunction 5 8.80 9.284  
TAC + Polycythemia 
Normal 9 6.22 1.716 0.005 
Dysfunction 4 4.00 .000  
 
RESULT 
26 patients developed polycythemia  
Association of polycythemia with graft dysfunction – not significant P value 0.597 
Among sub group analysis Tacrolimus based group developed more number of 
polycythemia compare to cyclosporine group P value 0.005 
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CMV & HCV infections Vs Graft Function 
 Normal Dysfunction Total  P 
value 
  N % N % N % 
Type CMV 10 90 1 10 11 100 0.68 
 HCV 6 40 9 60 15 100 0.92 
 
 
CMV – CYTOMEGALO VIRUS 
HCV - HEPATITIS C VIRUS 
Results : 
CMV infection – 11 recipients 
No significant association with graft dysfunctions 
HCV infection – 15 recipients 
No significant association with graft dysfunctions 
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Analysis to identify the factors leading to kidney dysfunction  
Factors 
Unadjusted Adjusted 
OR 95% CI P-value OR 95% CI Pvalue 
Donor age 1.044 1.011 - 1.078 0.009 1.035 1.001 - 1.072 0.049 
Donor sex 
Female 
Male 
 
1.000 
0.686 
 
 
0.346 - 1.361 
 
 
0.281 
- - - 
Recipient age Age 1.001 0.965 - 1.039 0.943 - - - 
recipient sex 
Female 
Male 
 
1.000 
3.292 
 
 
1.326 - 8.177 
 
 
0.010 
 
 
3.306 
 
 
1.292 - 8.459 
 
 
0.013 
Cold Isch Time 0.997 0.996 - 0.999 0.014    
HLATYPE 
Nil Match 
HLA 2 
Full match 
 
1.000 
3.022 
5.333 
 
 
1.349 - 6.771 
1.079 - 26.358 
 
 
0.007 
0.040 
- - - 
CR1.2 day 0.936 0.869 - 1.009 0.085 - - - 
CSA + 
No 
Yes 
 
1.000 
2.817 
 
 
1.441 - 5.511 
 
 
0.002 
 
 
2.437 
 
 
1.198 - 4.959 
 
 
0.039 
TAC + 
No 
Yes 
 
1.000 
0.378 
 
 
0.192 - 0.743 
 
 
0.005 
- - - 
 
ALL RESULTS ENTERED IN X L SHEET 
FOLLOWING TEST WERE CARRIED OUT TO ASSES THE SIGNIFICANCE 
1. TO COMPARE MEAN VALUE STUENT T TEST WAS USED 
 
2. TO COMPARE PROPORTION CHI SQUARE TEST WAS USED 
 
3. TO IDENTIFY FACTORS INFLUENCING DYSFUNCTION, SIMPLE 
AND MULTIPLE LOGISTIC REGRESSION WAS USED 
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DISCUSSION 
 A total of   155 transplant recipients were regularly followed up in nephrology 
outpatient department from 2009 October to march2011. Out of these 155 recipients, 
66 recipients had developed graft dysfunction.   Among the 66 recipients, 57 were live 
related first degree recipients, 7 were cadaver graft recipients and 2 were spousal 
transplant recipients. 
 Delayed graft function (defined as those required hemodialysis in immediate 
postoperative period) was noted in   7 recipients. All of them were cadaver transplant 
recipients and they required two to three hemodialysis session during the post 
operative period. All of them recovered completely and none of them developed graft 
dysfunction during study period.      
 Slow graft function (SGF defines a group of recipients in whom plasma 
creatinine level of greater than 3 mg/dL and no dialysis required during the first week 
of transplant) was noted in 8 out of 155 recipients.  Out of eight, three were cadaver 
recipients and five were live donor recipients.   Among the 8 recipients three had 
persistent Graft dysfunction more than a month after transplant. Hence renal biopsy 
was carried out after ruling out the other causes.  The Biopsy findings revealed acute 
tubular necrosis is the cause for dysfunction in all the three cases. The above said 
three recipients continued to have raised creatinine more than 1.5. 
 All the patients were started on triple drug immuno suppression (Tacrolimus 
/Cyclosporine,  Azathioprine / Mycophenolate, and prednisone).  No induction 
therapy was given for cadaver and spousal transplant recipient.  
 Out of 66 graft dysfunction (GDF) who underwent biopsy categorized as 
follows: 
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 Antibody mediated rejection -2  
Acute cellular rejection -13 
Acute tubular necrosis - 9 
Thrombotic microangiopathy -6 
Chronic allograft nephropathy -28 
Drug toxicity - 6 
 Non specific tubular changes-1 
Nuetrophilic infiltration   suggestive of infection-2.   
Combined lesion-3  
Acute cellular rejection with thrombotic microangipathy-2, 
Chronic allograft dysfunction with mild cellular rejection-1. 
 Acute antibody mediated rejection was observed in 2 of the graft dysfunction 
recipients. Both of them were treated with plasmaphersis, and hemodialysis.  No ATG 
were given as a rescue therapy due to financial constraint. There was no improvement 
in Graft function in these recipients. At present they are on maintenance 
Hemodialysis. 
Those who have biopsy proven acute cellular rejection (13) were treated with 
methyl prednisone pulse therapy.  Among the above 13 recipients, 2 were cadaver and 
remaining 11 were live donor recipients.  HLA matching was carried out in live donor 
and recipients.  It was found that one had full match, remaining 9 had haplomatch and 
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one had only one antigen match. HLA typing was not done for cadaver transplant 
recipients or donors. Out of 13 recipients, 7 were on cyclosporine regimen and 8 were 
on Tacrolimus regimen. There was an improvement in creatinine in eight out of 
thirteen recipients following methyl pulse therapy.  Remaining 5 recipients 
maintained the same creatinine without further raise.  Those who were on 
cyclosporine regimen were switched over to Tacrolimus.  
 Acute tubular necrosis (ATN) was observed in 9, out of 66 Dysfunction 
recipients. Among the 9, 6 had ATN within three months and remaining three (late 
group) had within six months after transplant. Out of six, three had ATN in the(early 
group) immediate post operative period (slow graft function) and in remaining three 
graft dysfunction(intermediate group) were identified during their follow up and 
subjected to biopsy after ruling out other causes. The cause for ATN in late group was  
diarrhoeal disease in 2 cases and pyrexia of unknown origin in another case ,improved 
after intravenous antibiotics. In all three(late group) recipients maintained high 
creatinine more than 2 for three weeks and subjected to biopsy.  Among them eight 
recovered completely. One had underlying chronic changes and creatinine remains   
stable till date without further rise. 
 Thrombotic microangipathy (TMA) was observed in six recipients. Out of the 
six TMA, 4 were on CSA and 2 were on TAC based regimen. All of them developed 
de novo TMA in the graft.  LDH and peripheral smear study were done for all the 
above six recipients but were not sensitive to predict TMA.  Calcinuerin based 
immuno suppression were withdrawn in all cases. Sirolimus was started on two 
recipients.    
 Twenty eight (28) recipients had chronic allograft nephropathy (CAN). Out of 
this 28, 24 were males and 4 were females.  Two were cadaver transplant recipient 
and remaining 26 were live donor recipients. Twenty three (23) out of 28 recipients 
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received organs from donors more than 40 yrs of age. Among them 25 were on 
cyclosporine based immunosuppression.  Among the 28 CAN recipients, three had 
graft loss and are on maintenance of hemodialysis. On looking into the duration, 4 had 
CAN within a period of 4 months, 8 developed CAN within 6 months and 12 
developed more than 1 year after transplant. 
 Biopsy proven calcinuerin toxicity was observed in 6 recipients. Among them 
4 were on CSA based and 2 were on TAC based regimen. All of them had undergone 
frequent drug level (trough) monitoring and dosage was adjusted according to the 
level. All of them are maintaining stable creatinine.   
 One recipient developed transplant renal artery stenosis 3 months after 
transplant and underwent renal artery stenting. Even after stenting graft function did 
not improve and She underwent renal biopsy. Biopsy showed ischemic 
glomerulonephritis. 
 Out of 66 recipients, three recipients (3) had biopsy proven IgA nephropathy. 
Among them 2 had recurrent IgA and one had de novo IgA in the graft.   
 Univariate and multivariate analysis were done for all the parameters which 
were taken for analysis: 
1. The association of graft function with donor age was analyzed. The mean age 
group of normal graft was 39 yrs compared to 44 yrs of dysfunction group. 
The association between donor age and graft dysfunction is significant P 
0.005.  The study done by jhon swanson et all & Fernando G cosio et all 
confirmed that increased donor age correlates with reduced allograft 
survival(52) 
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2. Most of the donors in this study were female, particularly live donor 
transplant.  Donor gender was analyzed with graft dysfunction. In this study 
the association is statistically significant. The study done by Neugarten J et 
all & Martin Zeier et all confirms that longevity of graft survival is affected 
when female kidneys were transplanted to male recipients(53). The gender 
effect is more in case of young donors (16 to 45 yr) compared with older 
donors (45 yr). The proposed hypothesis is nephron under dosing 
3. Donor blood group was analyzed with graft dysfunction.  Dysfunction group 
received kidneys are mostly from ‘B’ group donors. The association of donor 
blood group with graft dysfunction is not significant. 
4. Side of the kidney (right or left) and number of renal arteries were studied. In 
live donor transplantation left side is mostly preferred due to the technical 
reasons, provided left side has single renal artery. In this study out of 166 
recipients, 140 received left side kidney. While looking into the number of 
renal arteries, eleven (11) had double renal artery and the remaining were 
single. Among the 11 double renal arteries 8 were cadaver donors. Side of the 
kidney and number of renal artery do not show statistical significance with 
graft dysfunction. 
 
5. Recipient age was studied. In this study most of them were young recipients of 
age less than 35 yrs. Mean age group was 30 yrs in both arms. Recipient age 
does not show significant correlation with graft dysfunction. 
 
6. Epidemiology study by Dorry L. et all showed that women had 11% less 
access to kidney transplantation than men(54).   This study also confirms that 
access to kindly transplantation is better in males 80% than females 20% (132 
male and 23 female recipients,).  
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7. The association between male recipients with graft dysfunction was significant 
in this study (P value 0.008).This may be due to the fact that most of them 
were received graft from female donors. A study by Vereerstraeten P et all  
showed that  Inferior graft outcome when kidneys of female donors were 
transplanted into male recipients and also showed significantly higher 
incidence of rejections in male recipients who received organs from female 
donors(55). It is also observed in this study.     
                         
8. The association of Recipient blood group, duration of hemodialysis (months) 
and native kidney disease were taken for analysis. In this study it was 
observed that more ‘B’ group recipients developed graft dysfunction and mean 
duration of hemodialysis is eight months. The association of Recipient blood 
group, duration of hemodialysis (months) and native kidney disease with graft 
function is not significant. 
9. HLA mismatch were analyzed. Out of 165 recipients,  104 had haplomatch , 8 
had full match,  one had nil match and  not done in 42 recipients (35 cadaver 
and 6 spousal donors),  .  There is a statistically significant association 
between HLA mismatch with graft dysfunction (P value 0.012). Studies done 
by Halloran etall and Leepc , terasaki et all showed that there is a 
significant association between HLA mismatches and graft 
dysfunction(56),(57). This finding is also validated in this study.  
10. Influence of Tissue cross match over graft dysfunction was taken up for 
analysis.  In this study, most of the cross match reports vary between 5 to 10 
%. The association of cross match with graft dysfunction is not significant.  
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11. A study done by Stefan gunthertullius et all  compared  cold ischemia time 
and donor age  with graft dysfunction and confirmed that prolonged ischemic 
time > 120 mts affects graft survival significantly  in case of live donor 
transplants(58). Cold ischemic time varies between cadaver and live donor 
recipients due to transportation of organs from different places ( mean -  
514minutes in cadaver compare to 54 minutes in live donor grafts ).. In 
this study the association is not significant may be due to small sample size of 
cadaver donors and large   pool of live donor recipient.   
 
12. No statistically significant association between day one creatinine, discharge 
creatinine and urine output in first postoperative day with graft dysfunction 
13. Post operative Days required to reach creatinine of 1.2 were taken up for 
study. A study by Magaligiral-Classe et all , showed that  Delayed graft 
function of more than six days strongly by normal group compare to 
dysfunction group (8 days) to reach baseline creatinine of 1.2 and confirms the 
association of delayed function with graft dysfunction(59) 
14. Post transplant Hemodialysis (HD) done in 14 transplant recipients. Among 
them, 6 were in the immediate post operative period (delayed graft function) 
and remaining 8 recipients underwent HD for varying period after transplant 
for graft dysfunction. Association between hemodialysis and graft dysfunction 
is not significant in this study.  This is discordant with that study done by 
Henkboom et all, showed  that significant association between Delayed graft 
function and poor long term graft survival(60). This may be due to small 
sample size of delayed graft function recipients. Out of 13, five (5) developed 
chronic allograft loss (  CAN 3, AMR 2), presently they are on maintenance 
HD 
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15. 13 transplant recipients developed significant post operative events. There is 
no statistically significant association between the events and graft 
dysfunction. Among the subgroup analysis 9 pt in normal function group had 
intra and post operative events compare to 4 in dysfunction group. 
16. All patients were started on triple drug immunosuppression (csa+aza/  
csa+mmf, or Tac +aza /  Tac + mmf  and prednisone).  All patient received 
steroids either 1mg/ kg in case of csa group, or 0.5 mg in case of tac group and 
gradually dose tapered and maintained 0.2 mg / kg dose thorough their life. No 
steroid free or withdrawal protocols were followed. High risk recipients 
(cadaver, spousal and graft dysfunction) were started on tacrolimus and mmf 
regimen. Among the 155 pts 80 were on csa +aza, 17 were csa+mmf, 21 were 
tac+asa, 46 were tac + mmf regimen. Statistical analysis done for csa and tac 
verses graft function. Among them who are in csa based regimen had number 
graft dysfunction p = .001 probably due to overdosing, under dosing, non 
availability of drug level to monitoring toxicity in the early periods and drug 
toxicity. This observation is confirmed in a study by Marika A. Artzaetall   
that conversion of csa to Tacrolimus slow down the progression of 
dysfunction(61)    
17. New onset of diabetes mellitus after transplant (NODAT) was analyzed 
between normal and dysfunction group. Difference is not statistically 
significant between the groups. Among the subgroup analysis with age, 
recipients with age more than 30 developed more NODAT compare to less 
than 30 yrs P value .039. further subgroup analysis of incidence of NODAT 
between tacro based immunosuppression with cyclosporine regimen , more 
number of patient in tacro based group developed NODAT but statistically not 
significant .   
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18. Polycythemia was observed in 26 post transplant recipients. Influence of 
polycythemia over graft function is not statistically significant. There is a 
significant (P= 0.03 ) increase in  incidence of  polycythemia in tacro 
based regimen. This may be due to more number of normally functioning 
graft in tacro group.  
 Among the infection, cytomegalovirus & hepatitis c virus were taken up for 
analysis.11 recipients developed  
19. CMV infection as confirmed by PP65Ag  .Out of 11,  3 were positive after 3 
months, 6 after 7 months, 2 after one year after transplant. All of them were 
treated. One recipient developed graft dysfunction. The association is not 
significant. 
20. HCV infection was noted in 14 of our recipients.  Among the 14, two were 
detected   prior to transplant .In this study,  the association between HCV 
infection and graft dysfunction is not significant  
21. Multivariate analysis was done by using logistic Regression analysis to 
identify the factors leading to kidney dysfunction.  Among the factors donor 
age, recipient sex and cyclosporine showed statistically significant association 
with graft dysfunction. This is concordant with a study done by A.E. 
Courtney et all(62). 
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CONCLUSION 
According to Univariate analysis following conclusion were made 
¾ Tacrolimus gives a better graft survival than cyclosporine for both live 
and cadaveric transplants. 
¾  Donor age has significant impact on  long term  graft survival; younger 
the donor better the outcome  
¾ With female donors the graft dysfunction is more, may be due to 
difference in antigencity and smaller renal mass  
¾ The Male recipients do worse than female recipients; probably due to 
female recipients has higher degree of sensitization to HLA antigen. 
¾ Blood group, cross match results, day one urine output, First post 
operative day creatinine, discharge creatinine are not having significant 
association with cause graft dysfunction 
¾   Delayed graft function has significant impact on long term graft survival 
according to Univariate analysis 
¾ Side of the kidney , number of blood vessels, post operative events are not 
statistically significant to cause graft dysfunction 
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MULTIVARIATE ANALYSIS 
¾ Multivariate analysis was carried out for all the parameters to assess the 
significance.  The following parameters has more significant association 
with graft dysfunction. 
1. Donor age, 
2.  recipient sex – male recipient has more significant graft dysfunction  
3.  cyclosporine compare to tacrolimus has more significant association 
with graft dysfunction. 
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subramani normal cadaver 45 m 42 o cgn 36 Not done Not done 10 480 36 m cadaver o left single 1.6 5 1.2 12000 y 2 9
JAYAKUMAR SGF normal cadaver 30 M 42 B CGN iga 5 Not done Not done 15 540 29 M cadaver B RIGHT single 4.8 21 1.1 6370 pancreat y y 1 7
REVATHY normal cadaver 25 F 35 O CGN 24 Not done Not done 15 420 36 m cadaver o RIGHT single 1 2 0.8 17600 SEPSIS y
palani normal cadaver 37 m 42 o cgn 38 Not done Not done 10 120 15 f cadaver o right single 2.3 14 1.2 12000 y
elavarasan normal cadaver 22 m 36 ab CGN OBSTR 24 Not done Not done 15 600 12 M cadaver ab left single 2.4 3 1 7700 y 2
devi normal cadaver 29 m 35 o cin 6 Not done Not done 15 300 36 m cadaver o RIGHT single 1.7 14 1.2 7300 y
meeramohideen dys cadaver 35 m 46 o cgn IgA 9 Not done Not done 15 600 38 m cadaver o left single 2.2 4 1.4 26100 y 2 2500 1.5 4 y
abdul rahim normal cadaver 30 m 43 ab cgn 13 Not done Not done 15 420 31 m cadaver ab RIGHT single 2.2 3 1 5500 y 2 4 y
nasirali DGF normal cadaver 25 m 75 o cgn 36 Not done Not done 15 840 21 m cadaver o RIGHT single 10.2 60 2.2 1450 2 y 1
amuthulvalli normal cadaver 20 f 42 b cgn 8 Not done Not done 15 600 50 m cadaver o RIGHT single 5.5 6 1.3 3650 lymphocele y 7
narasingan DGF normal cadaver 23 m 46 b cgn 18 Not done Not done 15 240 42 m cadaver b left DOUBLE 5.6 19 1.2 625 1 pancreatitis y
sajeevan normal cadaver 32 m 42 a cgn 12 Not done Not done 15 300 33 m cadaver a rright single 1.9 5 1.1 3200 y
dasaprakash dys cadaver 36 m 52 b cgn 8 Not done Not done 10 600 45 m cadaver b rright double 3.8 7 1.2 5450 y 1500 2 6 y
abdulmunaf dys cadaver 38 m 48 a cgn 24 Not done Not done 10 120 40 m cadaver a left single 2.1 7 1.1 5200 y 1500 2 60 y
devaraj normal cadaver 45 m 52 o cgn 14 Not done Not done 10 660 24 m cadaver o left single 3 4 1 4300 y
riyazali normal cadaver 25 m 42 o cgn iga 8 Not done Not done 15 330 29 m cadaver o right double 4.8 9 1 4650 y 5 5
ponkodi normal cadaver 45 f 42 b cgn 6 Not done Not done 10 480 45 m cadaver b left single 2.5 4 1.1 9500 y
suja normal cadaver 29 f 42 o cgn 12 Not done Not done 10 420 23 m cadaver o right double 2.4 5 1.1 2400 y
periyaswamy normal cadaver 29 m 38 a cgn 12 Not done Not done 15 420 29 m cadaver a left single 5.3 1 1.2 4280 y
nirmala normal cadaver 34 f 41 o cgn 24 Not done Not done 10 480 19 m cadaver o let single 6.2 12 1 2000 SEPIS y
kondyaraj dys cadaver 32 m 40 o cgn 36 Not done Not done 10 600 49 m cadaver o left three 3 3 1 1500 8 y 6 3500 2 6  y
balaraman normal cadaver 32 m 40 b cgn 10 Not done Not done 10 480 26 m cadaver b left single 3 6 1 3400 y 4 4 2000 2 3 y
balakrishnan DGF normal cadaver 31 m 45 b cgn 24 Not done Not done 10 720 48 m cadaver b left double 5 18 1.4 390 3 y 6 6
lillytherasa SGF normal cadaver 29 f 50 b cgn 24 Not done Not done 15 720 56 f cadaver b left three 3 25 1.5 4000 y 8
sasikumar normal cadaver 29 m 35 a cgn 1 Not done Not done 10 180 15 f cadaver a left double 2 4 1 21000 y
baskar normal cadaver 38 m 40 ab cgn 8 Not done Not done 5 600 20 f cadaver ab left single 2 8 1.2 5750 5 y 4 2500 2 6 y
dasan SGF dys cadaver 48 m 51 o CIN adpkd 24 Not done Not done 10 600 39 m cadaver o left single 4 21 1.2 5000 sepsis y 1 2000 2 1 y y
renuka normal cadaver 34 f 41 b cgn iga 36 Not done Not done 5 420 19 f cadaver o left single 2 3 1 2125 y
gopikrishnan DGF normal cadaver 40 m 45 b cgn fsgs 6 Not done Not done 5 600 57 m cadaver b left single 3 9 1 3000 2 y 4
prema DGF dgf cadaver 35 f 60 a cgn 23 Not done Not done 5 720 18 f cadaver a left double 5 15 1.2 500 2 SEPSIS y
kumar normal cadaver 32 m 35 a cgn iga 10 Not done Not done 10 480 22 m cadaver a right double 4 12 1.2 6150 y 6
kamaraj DGF dgf cadaver 43 m 45 o cgn 8 Not done Not done 10 300 50 m cadaver o left single 6 20 1.4 300 2 y 6
arumugam normal cadaver 35 m 40 a cgn 26 Not done Not done 10 480 25 m cadaver a left single 3 3 1 7550 y
ramadoss DGF dgf cadaver 57 m 38 b cgn adpkd 8 Not done Not done 10 480 60 f cadaver b right single 5 26 1.6 1620 2 y 2 y
balagi normal cadaver 32 m 42 o cgn 34 Not done Not done 10 300 20 m cadaver o right single 3 3 1.2 18050 y
ARJUNAN dys live 32 m 41 b cgn 5 Full Match 10 10 5 45 35 f sister b left single 1.7 6 1.2 6500 SEPSIS y 7 3000 2 9 yes  
palani dys live 29 m 57 b CGN 7 HLA 2 5 10 5 45 46 f mother b left single 1.1 4 1.1 16300 YES 4 1500 2 8 YES YES
gopal dys live 35 m 45 b cgn 4 HLA 2 5 10 5 85 45 f mother b left DOUBLE 2 6 1.4 23650 yes 3 3500 2 7 iga
sumitha dys live 18 f 25 ab cgn IgA 8 HLA 2 10 10 7 55 48 f mother AB left single 2.8 5 1.2 8500 y 2000 1.6 72 ischemic.GN 3month
sasikumar dys live 35 m 35 b cgn 6 Not done 10 10 5 55 28 f SPOUSE B left single 1.7 10 1.3 14150 8 Y 3000 2 6 Y
saraswathy dys live 35 f 36 b cgn 6 HLA 2 10 10 5 55 50 f mother b left single 1.2 2 1 17850 y 7 1 1200 1.7 6 y 
shankar dys live 45 m 45 a cgn 3 HLA 2 10 10 6 55 63 m brother a left single 3.2 5 1.2 7500 pred+aza 1000 2 5 y 
venkatesan dys live 29 m 39 a cgn 3 HLA 2 10 10 6 53 55 m brother a left single 2.6 5 1.5 8150 y 1000 1.8 4 y
ramamoorthy dys live 56 m 42 o cgn 5 HLA 2 10 10 5 53 57 f sister o left single 3.8 5 1.5 6800 y 60 1500 2 4 y 
simsone dys live 26 m 40 b cin 4 HLA 2 5 10 6 48 59 f mother b left single 2.3 6 1.2 8000 y 3 2000 2 48 y
tamilarasan dys live 20 m 40 b cgn 5 HLA 2 5 10 5 45 45 m father B left single 1.6 2 1.2 15300 Y 2000 1.8 46 Y Y
KAVIRAJAN dys live 24 M 52 B CIN 6 HLA 2 10 10 7 59 45 F mother B left single 3.5 2 1.2 14150 Y 5 2000 2.1 42 Y
baskar dys live 33 m 36 a cgn 5 HLA 2 10 10 8 52 40 f mother a left single 3.2 4 1.2 11500 y 1200 3.3 12 y ,chr chan
raman dys live 24 m 43 a cgn 6 HLA 2 10 10 5 58 43 f mother a left single 2.3 4 1.1 12050 y 500 1.8 3 y 1 y
ramachandran dys live 37 m 36 b cin 6 HLA 2 10 10 5 55 55 m father b left single 2 4 1 19200 y y 1000 2 29 Y
sadasivam dys live 33 m 42 a cgn 5 HLA 2 5 10 7 58 52 m father a left single 3.2 7 1.2 9630 y 11 750 3 26 y
sathiskumar dys live 21 m 52 b cgn 4 HLA 2 5 10 6 60 48 f mother b left single 2.9 4 1 13600 y y04.09 14 1250 2.4 24 y
SARANYA dys live 17 f 25 a cgn 2 HLA 2 10 10 5 55 32 f mother a left single 1 1 1 148000 PANCREATI y y04.08 32 1000 2 20 y
sakthivel dys live 24 m 45 b cgn 5 HLA 2 10 10 5 55 45 f mother b left single 1.5 3 1 9950 y y 5 500 3 19 y
murugasen dys live 26 m 42 o cgn SLE 5 HLA 2 10 10 5 55 48 f mother o left single 1.5 5 1 19350 y siro 17 1250 3.5 17 1 y int.lym.inf01.07
shamregis dys live 21 m 42 b cgn 4 HLA 2 10 10 8 52 49 f mother b left single 1 1 1 19650 y siro 1500 2 14 y
vijyakumar dys live 25 m 40 o cin 5 HLA 2 10 10 10 60 34 f mother o left single 2.6 3 1.1 11350 y 1 1250 2.6 12 y
mohan dys live 24 m 35 o CGN 4 HLA 2 10 10 7 50 50 f mother o left single 1.6 3 1 9250 y 1200 3 12 y
saleem dys live 48 m 42 b cgn 5 HLA 2 10 10 5 55 35 f sister b left single 3.5 5 1 8500 y 3 1000 2.5 11 y
raffic dys live 24 m 45 ab cgn 6 HLA 2 10 10 5 55 48 f mother a left single 2.3 3 1 5800 1250 1.7 10 y
ravichandran dys live 30 m 42 o cin 5 HLA 2 10 10 5 50 35 f sister o left single 2.5 5 1 5500 y y 1 750 2 10 y
subramani dys live 40 m 45 a cgn 5 HLA 2 10 10 7 55 38 f sister a left single 3 4 1 12750 y 2 1200 2 10 y
kadiracen dys live 39 m 44 a cgn 4 HLA2 5 10 3 48 44 f sister a left single 2 4 1.2 4500 y y 24 500 2.5 10 y
vijyapandian dys live 29 m 58 b cgn glo.scleros 3 HLA 2 5 10 5 40 49 f mother b left single 5.8 6 1.2 13850 y
chandrasekar dys live 23 m 42 b cgn 5 HLA2 5 5 3 47 50 m father b left single 2.6 5 1.1 17950 y y / 02.11 3 1500 2.3 185 y
marimuthu dys live 32 m 42 o cgn 4 HLA 2 5 5 5 58 58 m father o left single 3.5 5 1.2 8500 8 1250 2.8 77 y
logeswaran dys live 24 m 40 b cgn 5 Full Match 10 10 5 55 58 m father b left single 2.1 3 1.1 8500 y y / 03.08 8 1500 1.7 51 y reflue hun
SHANKAR dys live 48 m 50 o cgn 9 HLA2 10 10 5 60 32 m brother o left single 2.6 5 1.1 7500 1250 2.3 25 y
gokulvardarajan dys live 21 m 40 o cgn fsgs 5 HLA 2 5 10 5 65 50 f mother o left single 3.4 8 1.7 12900 6 y y 1000 1.5 24 y
RAMESH DYS live 19 M 30 O cgn IGA 6 HLA2 5 5 5 50 32 F mother O left single 2.3 2 1 20550 Y Y 750 1.7 21 y
raja dys live 24 m 42 o cgn iga 5 HLA 2 5 10 5 60 45 f mother o eft single 3.5 5 1 7250 y 750 3 19 iga
chengamuthu dys live 27 m 42 o cin 4 HLA 2 5 10 5 55 48 f mother o left single 3 6 1.1 8560 y 1250 3 19 y
deenadayalan dys live 35 M 45 a cgn 6 HLA 2 10 10 5 50 35 f sister o left single 4.8 6 1 11250 sepsis y 1200 2.5 14 y
anandan dys live 30 m 50 b cin 5 HLA 2 10 10 5 60 55 f mother b left single 2.5 5 1.2 8500 y 500 2 12 y
ramesh dys live 30 m 50 a CIN OBSTRUT 6 HLA 2 10 5 5 60 45 f sister a left single 3.1 5 1.1 8500 y 900 9 10 y
karthikeyen dys live 34 m 45 ab cin 5 HLA 2 10 5 3 60 50 f mother b left single 2.4 5 1 23200 y y 4 1250 2.5 10 y
julian dys live 39 m 50 b cgn 8 Not done 10 10 5 45 34 f SPOUSE b left single 3.2 2 1 22950 y 2 600 1.5 5 y y
srinivasan dys live 23 m 42 o cgn iga 5 HLA 2 10 10 4 50 30 m brother o left single 2 3 0.7 5500 y 900 1.7 4 iga
buhari dys live 30 m 35 a cgn 2 HLA 2 10 10 3 57 48 f mother a left single 2.6 4 1 7500 y 1200 2 4 y
saraswathy dys live 32 m 40 a cgn 6 HLA2 10 10 5 55 54 F mother a left single 3 4 1.2 8600 8 1200 1.7 6 y
mayakrishnan normal live 35 M 52 O CGN 5 HLA 2 10 10 3 50 45 f mother o left single 1.7 4 1 21200 yes yes / 2.09
vivekanandan normal live 18 m 35 a cin 7 HLA 2 5 10 5 50 40 f mother a left single 2 7 1.2 16600 yes
dhanalakshmi normal live 39 f 45 a cgn mpgn 5 HLA 2 10 10 5 60 35 f sister A left single 1.1 2 0.9 20900 yes
prasanth SGF sgf live 35 m 55 b CGN 4 HLA2 10 10 5 55 45 f mother b left single 3 21 1.1 16950 y y /26/2.10
jayaprakassh SGF sgf live 31 m 62 o cgn 8 HLA 2 10 10 5 55 48 f mother o RIGHT single 3.4 NEVER 1.6 4580 y y / 11.3.10 1
KUMAR normal live 32 M 54 AB cgn 5 Not done 10 10 7 50 28 f spouse a left single 2.6 3 1.2 5100 y
mangeswaran SGF sgf live 35 m 45 b cgn 6 HLA 2 10 15 6 55 52 f mother B left single 1.5 19 1.2 18000 pnumnia ,sepsis y 1
dhanalakshmi normal live 45 f 39 o cin 5 HLA 2 10 10 5 55 40 m brother o left single 1.1 2 0.8 23350 1
bhuveneswari normal live 17 f 36 ab cgn 4 HLA 2 10 10 5 55 45 f mother ab left single 3.6 5 0.8 4360 y
nainar mohamed normal live 36 m 42 b cgn 6 HLA 2 10 10 5 50 45 f mother b left single 2.8 2 1 8660 y 8
menaga SGF sgf live 22 f 41 b cgn IgA 6 Full Match 10 10 5 55 51 f mother b left single 3.8 2 1.5 8900 y 300 1.7 1 y
balagi normal live 17 m 43 a CGN 6 HLA 2 10 10 8 45 45 f mother a left single 3 4 1.2 1.2 y 500 2 6 y
ravi dysfunct live 30 m 42 b cin 5 HLA 2 10 10 7 58 50 m father b left single 1.9 3 1 13250 y 12
shabudeen normal live 23 m 40 o cgn 6 HLA 2 5 10 5 55 48 f mother o left single 3.4 2 1 15950 y 24
nagaraj normal live 32 m 45 o cgn 6 10 10 6 60 30 f SPOUSE O left single 1.6 5 1 16100 Y
gandhi normal live 31 m 43 o cgn 5 HLA 2 10 10 5 58 40 m brother o left single 1.8 4 1 9000 y 48
tamilarasan normal live 18 m 36 b cin 5 HLA 2 10 10 5 58 52 m father b left single 1.1 1 1 15300 y
MERCYANNAMERY SGF SGF live 43 F 48 b cin 4 Full Match 10 10 10 55 37 f sister b left single 1.8 14 2 5400 y 12 800 2 1 y
rajeswari normal live 29 f 38 o cgn 4 HLA 2 10 10 5 57 49 f mother o left single 1.9 5 1.2 13300 y
hemavathy normal live 16 f 32 b cgn 4 HLA 2 5 10 5 45 45 f mother b left single 2.4 4 1.2 5500 y
THANGARAJ normal live 32 M 42 B CGN schmic 4 HLA2 10 10 15 50 39 F sister B left single 2.6 14 1.4 13100 Y Y 10
RAMAMOORTHY normal live 41 M 50 A CGN 5 Not done 5 10 3 50 38 F SPOUSE O left single 2.3 4 1.3 9500 Y
t.mohan normal live 36 m 42 b cgn 3 Full Match 5 10 10 50 55 f mother b left single 2.3 5 1.1 17300 y
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ramesh normal live 32 m 45 o cgn 4 HLA 2 5 5 3 55 55 m father o left single 1.6 6 1.2 10500 y
madanagopal dysfunct live 37 m 45 o cgn 4 Full Match 5 5 3 45 40 m brother o left single 3.2 4 1.1 8500 y 3 350 2 1 y
jeevarathinam normal live 26 m 38 b cin 2 HLA 2 5 5 4 54 45 f mother b left single 2.5 5 1.1 8200 pancreatitis 6
thirunavukarasu normal live 32 m 40 o cin 6 HLA 2 10 10 5 58 45 f mother o left single 3 6 1.2 8000
kumaravel dysfunct live 27 m 45 o cgn 2 HLA 2 5 5 5 46 48 f mother o left single 2.5 5 1.1 6500 8 y 2300 2 4 y
elumalai normal live 16 m 42 b cgn 5 HLA 2 10 15 5 60 42 m father b left single 1.1 3 0.8 9650 y y
ramamoorthy normal live 31 m 43 a cgn 5 HLA 2 10 10 6 54 42 f sister a left single 2.5 2 1.1 5350 y
MANIKANDAN normal live 21 m 35 a cgn iga 5 HLA 2 5 5 5 55 21 f mother a left double 3.7 3 1 8500 y
shanmugam normal live 26 m 35 b cgn dm neph 5 HLA 2 5 5 5 55 46 f mother b left single 2.5 5 1 8500 y
ksirajan normal live 26 m 35 b cgn 6 HLA 2 5 10 3 45 55 f mother b left single 2.5 5 1.1 5600 y
navaneetham normal live 29 m 40 a cgn 5 nil 10 10 5 55 48 f AUNT a left single 3 5 1.1 8200 850 2 48 Y
sakthivel normal live 28 m 42 a cgn 5 HLA 2 10 10 5 55 35 m brother a left single 2.8 6 1.3 7400 y 2 infection
shankar normal live 30 m 32 b cgn 42 HLA 2 25 10 3 45 48 f mother b left single 3.8 2 0.8 19200 y 1 4 1.9 y
babu normal live 34 m 45 b cgn iga 6 Not done 10 10 7 90 24 f spouse b left double 4.4 3 1.5 17950 y 1
maheswaran normal live 28 m 42 a cgn ht nephro 5 HLA 2 10 10 5 48 40 f mother a left single 3 4 1.1 7560 y
venkatesan normal live 25 m 52 b cgn 5 HLA 2 10 10 5 60 48 f mother b left single 2.4 6 1.1 11650 y 3 7
fathima normal live 25 f 35 o CGN SLE 7 HLA 2 10 10 3 50 49 f mother o left single 1.2 1 1 19850 y
elumalai normal live 24 m 42 o cgn 5 HLA 2 5 5 5 45 45 f mother o left single 2 3 1 10800 y
kathirvel normal live 30 M 52 o cgn 4 HLA 2 5 5 5 55 53 f mother o left single 1.7 4 1.1 18050 y 8 7
sentamilraja normal live 29 m 52 o cgn 8 HLA 2 10 10 5 55 46 f mother o left single 2.3 5 1 8000 y 5
malathy dysfunct live 20 f 42 b cgn 5 HLA 2 10 10 6 54 35 f sister b left single 2.2 5 1 5400 y 1200 1.8 y
usha normal live 14 f 20 o cgn 2 HLA 2 10 10 5 50 30 f mother o left single 2 4 1 8500 y
mary normal live 23 f 35 a cgn 4 HLA 2 10 10 5 50 46 f mother a left single 2.5 4 1.1 8600 y
sakthivel dysfunct LIVE 25 M 48 B CGN 2 HLA 2 10 10 5 40 40 F mother B left single 2.5 6 1 15850 Y Y 3 1500 2.3 8 Y
stefen devakumar dysfunct live 48 m 42 o cgn 5 HLA 2 10 10 5 55 56 f sister o left single 1.8 5 1.2 7500 y 1500 2.3 10 y
mahesh dysfunct live 23 m 40 b cgn 5 HLA 2 5 5 15 60 45 f mother b left single 4.6 7 1.1 8355 y y 1000 1.8 10 Y
lakshmi normal live 45 f 40 b cgn fsgs 4 HLA 2 5 10 5 50 60 f mother b left single 2.7 4 1 8050 y
vinothkumar normal live 20 m 35 o cgn iga 5 HLA 2 5 10 5 50 50 f mother o left single 3.3 7 1.2 19150 y 4
gomathy normal live 35 f 48 b cgn 5 HLA 2 10 10 5 60 50 f sister b left single 2.5 6 1 7800 y 800 2 14 Y
vijyalakshmi normal live 37 f 45 o cgn 4 HLA 2 10 10 6 54 37 m brother o left single 2 3 1 9600 y y
srinivasan normal live 25 m 50 a cgn 5 HLA 2 10 10 5 80 21 m brother a left single 4.5 8 1.2 5850
devika normal live 42 f 35 o cgn 5 HLA 2 5 10 5 55 35 m brother o left single 2.5 5 1 8200 y
mugunthan normal live 19 M 36 O cgn reflux 8 HLA 2 5 5 3 58 46 F mother O left single 1.7 2 1.1 6550 y 4
thagera normal live 27 f 48 b cgn 5 HLA2 10 5 5 58 48 f mother b left single 2 3 1 5800 y
viswanathan normal live 38 m 42 b cgn 3 HLA 2 10 5 4 56 50 f mother b left single 2 4 1 6400 y
thulasi normal live 19 f 42 b cgn mpgn 5 Full Match 10 10 5 45 28 f sister b left single 1.3 2 0.9 20650 y 8
chakaravarthty normal live 53 m 50 o cgn 5 Full Match 10 10 5 55 52 m brother o left single 2 5 0.8 8500
subramanian normal live 40 m 35 a cgn 5 HLA2 5 5 5 55 55 f mother a left single 2.5 5 1 8500 y 4
bhavanandi normal live 35 m 46 b cgn 6 HLA 2 5 5 3 57 42 f sister b left single 2.5 6 1 7500
anitha normal live 20 F 54 a cgn 5 HLA 2 10 10 5 55 52 f mother a left single 2 3 1 8500 y 4
pongodi normal live 28 F 50 o cgn 4 HLA 2 10 10 5 55 54 f mother o left single 2 2 1.2 7800 y
murali normal live 26 m 45 o CIN OBSTR 4 HLA 2 10 10 3 47 47 f mother o left single 3 5 1.2 6800 y 24
umamaheswaran normal live 33 m 42 o cgn isch.gn 5 HLA 2 10 10 5 56 36 f sister o left single 2 2 1 8500 y 24
asokan normal live 32 m 40 o cin 6 HLA 2 10 10 5 55 43 f sister o left single 2 4 1 7500 y
balraj normal live 18 m 48 a cin 5 HLA 2 10 10 3 55 36 f mother a left single 2 2 1 19500 y
sulaiman normal live 27 m 42 ab cgn 5 HLA 2 10 10 3 50 32 m brother ab left single 2 1 1.1 20950 y
menaga normal live 52 f 48 b cgn isch.gn 12 HLA 2 10 10 5 55 32 f sister b left single 4.2 7 1.1 12000 y y
devagi normal live 21 f 27 o cgn 5 HLA 2 10 10 4 90 43 f mother o left single 1.5 3 1.2 17250 y
venkatesan normal live 28 m 45 o cgn dm 6 HLA 2 10 10 5 55 31 f sister o left single 1.5 2 1.2 20350 y 7
babu normal live 18 m 32 b cgn isch.gn 4 HLA 2 10 10 3 58 42 f mother b left single 2.1 3 1.1 6580 LYMPOCELEy
sathiskumar dys live 21 m 35 b cgn iga 8 hla2 10 5 5 64 46 m father b left single 2 4 1 8560 8 y y 6 2000 2.5 24 y
suresh dys live 29 m 57 b CGN 7 HLA 2 5 10 5 45 46 f mother b left single 1.1 4 1.1 16300 YES 4 1500 2 8 YES YES
mhd
mhd
